Ken Griffin Galectin Therapeutics Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 62,500 shares of GALT stock, worth $170,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,500

Previous 13,600 359.56%

Holding current value

$170,000

Previous $30,000 470.0%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.13 - $4.2 $50,476 - $99,531	-23,698 Reduced 96.64%	823 $1,000
Q1 2024 May 15, 2024	BUY	$1.6 - $2.44 $28,017 - $42,726	17,511 Added 249.8%	24,521 $58,000
Q4 2023 Feb 14, 2024	BUY	$1.6 - $2.18 $11,216 - $15,281	7,010 New	7,010 $11,000
Q2 2023 Aug 14, 2023	SELL	$1.32 - $2.08 $1,122 - $1,768	-850 Reduced 66.51%	428 $0
Q1 2023 May 15, 2023	SELL	$1.1 - $2.4 $90,591 - $197,654	-82,356 Reduced 98.47%	1,278 $2,000
Q4 2022 Feb 14, 2023	BUY	$1.03 - $1.66 $67,458 - $108,720	65,494 Added 361.05%	83,634 $94,000
Q3 2022 Nov 14, 2022	BUY	$1.31 - $2.48 $23,763 - $44,987	18,140 New	18,140 $29,000
Q4 2021 Feb 14, 2022	BUY	$2.07 - $3.8 $39,226 - $72,010	18,950 Added 77.56%	43,382 $89,000
Q3 2021 Nov 15, 2021	BUY	$2.59 - $4.15 $13,206 - $21,160	5,099 Added 26.37%	24,432 $95,000
Q4 2020 Feb 16, 2021	BUY	$2.24 - $2.87 $8,848 - $11,336	3,950 Added 25.68%	19,333 $43,000
Q2 2020 Aug 14, 2020	SELL	$1.66 - $3.15 $60,125 - $114,093	-36,220 Reduced 70.19%	15,383 $47,000
Q1 2020 May 15, 2020	BUY	$1.51 - $3.0 $61,173 - $121,536	40,512 Added 365.27%	51,603 $101,000
Q4 2019 Feb 14, 2020	SELL	$2.79 - $4.32 $22,194 - $34,365	-7,955 Reduced 41.77%	11,091 $32,000
Q3 2019 Nov 14, 2019	SELL	$3.0 - $4.05 $4,095 - $5,528	-1,365 Reduced 6.69%	19,046 $69,000
Q1 2019 May 15, 2019	SELL	$3.86 - $6.02 $1,219 - $1,902	-316 Reduced 1.52%	20,411 $0
Q4 2018 Feb 14, 2019	SELL	$3.43 - $5.74 $9,164 - $15,337	-2,672 Reduced 11.42%	20,727 $71,000
Q2 2018 Aug 10, 2018	SELL	$3.16 - $9.16 $139,504 - $404,386	-44,147 Reduced 65.36%	23,399 $0
Q1 2018 May 11, 2018	BUY	$3.78 - $5.97 $255,323 - $403,249	67,546 New	67,546 $320,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.57M

Call Options Held

1.16M

Put Options Held

1.98M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $162M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account